Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19()

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in Wuhan in December 2019, and has since caused a global pandemic. The efficacy of several drugs has been evaluated, and it is now evident that tocilizumab has a beneficial effect, especially combined with cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamata, Takaya, Tanino, Yoshinori, Nikaido, Takefumi, Minemura, Hiroyuki, Sato, Yuki, Togawa, Ryuichi, Watanabe, Natsumi, Yamada, Ryuki, Sato, Riko, Onuma, Takumi, Tomita, Hikaru, Saito, Mikako, Rikimaru, Mami, Suzuki, Yasuhito, Tsukada, Yasuhiko, Nakamura, Kiwamu, Kanemitsu, Keiji, Iseki, Ken, Shibata, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428329/
https://www.ncbi.nlm.nih.gov/pubmed/36057415
http://dx.doi.org/10.1016/j.jiac.2022.08.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428329/
https://www.ncbi.nlm.nih.gov/pubmed/36057415
http://dx.doi.org/10.1016/j.jiac.2022.08.021

Ejemplares similares